---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-033362"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:11:25.155578+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuwellis announces first commercial sale of QUELIMMUNE therapy for pediatric AKI/sepsis

## Summary
- First commercial sale of QUELIMMUNE to Cincinnati Children's Hospital for pediatric AKI/sepsis patients.
- QUELIMMUNE (Selective Cytopheretic Device) developed by SeaStar Medical; early data show 77% survival rate.
- Sale under exclusive US distribution agreement with SeaStar Medical (ICU); FDA Humanitarian Device Exemption.
- Dr. Stuart Goldstein, principal investigator, will integrate QUELIMMUNE as standard of care at Cincinnati Children's.
- CEO Nestor Jaramillo: milestone advances Nuwellis' pediatric business development strategy.

## SEC filing metadata
- accession: 0001140361-24-033362
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036124033362/0001140361-24-033362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036124033362/ef20032543_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-033362
- JSON: https://secwatch.observer/filing/0001140361-24-033362.json
- Plain text: https://secwatch.observer/filing/0001140361-24-033362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.